• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
COVID-19: how a self-monitoring checklist can empower early intervention and slow disease progression.新型冠状病毒肺炎:自我监测清单如何助力早期干预并减缓疾病进展
Environ Syst Decis. 2021;41(2):181-183. doi: 10.1007/s10669-021-09806-2. Epub 2021 Mar 8.
2
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.在普通人群中进行 SARS-CoV-2 监测的四种不同策略的有效性和成本效益(CoV-Surv 研究):一项关于集群随机、双因素对照试验的研究方案的结构化总结。
Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z.
3
Authors' response: Occupation and SARS-CoV-2 infection risk among workers during the first pandemic wave in Germany: potential for bias.作者回复:在德国首次大流行期间,工人的职业与 SARS-CoV-2 感染风险:潜在的偏见。
Scand J Work Environ Health. 2022 Sep 1;48(7):588-590. doi: 10.5271/sjweh.4061. Epub 2022 Sep 25.
4
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
5
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验(SAINT)评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力:一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
6
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
7
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体(RES-Q-HR):一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
8
[Health professionals facing the coronavirus disease 2019 (COVID-19) pandemic: What are the mental health risks?].面对2019冠状病毒病(COVID-19)大流行的卫生专业人员:心理健康风险有哪些?
Encephale. 2020 Jun;46(3S):S73-S80. doi: 10.1016/j.encep.2020.04.008. Epub 2020 Apr 22.
9
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.PROTECT 试验:羟氯喹对比观察支持用于预防或 COVID-19 早期治疗的一项集群随机对照研究:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 31;21(1):689. doi: 10.1186/s13063-020-04527-4.
10
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.新型冠状病毒病 2019(COVID-19)大流行期间癌症患者管理的实用方法:国际协作组。
Oncologist. 2020 Jun;25(6):e936-e945. doi: 10.1634/theoncologist.2020-0213. Epub 2020 Apr 27.

引用本文的文献

1
Evaluation of an automated CRISPR-based diagnostic tool for rapid detection of COVID-19.一种基于CRISPR的自动化诊断工具用于快速检测新型冠状病毒肺炎的评估
Heliyon. 2023 Feb;9(2):e13190. doi: 10.1016/j.heliyon.2023.e13190. Epub 2023 Jan 23.
2
Remote Follow-up of Self-isolating Patients With COVID-19 Using a Patient Portal: Protocol for a Mixed Methods Pilot Study (Opal-COVID Study).使用患者门户网站对新冠病毒病自我隔离患者进行远程随访:一项混合方法试点研究(蛋白石-新冠病毒病研究)方案
JMIR Res Protoc. 2022 Aug 18;11(8):e35760. doi: 10.2196/35760.
3
COVID-19 Pandemic and Equal Access to Vaccines.新冠疫情与疫苗的平等可及性
Vaccines (Basel). 2021 May 21;9(6):538. doi: 10.3390/vaccines9060538.
4
Algorithms and models for decision making in advanced technology systems.先进技术系统中决策的算法与模型。
Environ Syst Decis. 2021;41(2):179-180. doi: 10.1007/s10669-021-09816-0. Epub 2021 May 20.

本文引用的文献

1
Effect of early oxygen therapy and antiviral treatment on disease progression in patients with COVID-19: A retrospective study of medical charts in China.早期氧疗和抗病毒治疗对 COVID-19 患者疾病进展的影响:中国病历的回顾性研究。
PLoS Negl Trop Dis. 2021 Jan 6;15(1):e0009051. doi: 10.1371/journal.pntd.0009051. eCollection 2021 Jan.
2
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).多方面、高针对性、序贯、多药物早期门诊高危 SARS-CoV-2 感染(COVID-19)治疗。
Rev Cardiovasc Med. 2020 Dec 30;21(4):517-530. doi: 10.31083/j.rcm.2020.04.264.
3
Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis.伊维菌素作为 COVID-19 附加治疗的治疗潜力:系统评价和荟萃分析。
J Pharm Pharm Sci. 2020;23:462-469. doi: 10.18433/jpps31457.
4
Therapy for Early COVID-19: A Critical Need.早期新冠病毒病的治疗:迫切需求。
JAMA. 2020 Dec 1;324(21):2149-2150. doi: 10.1001/jama.2020.22813.
5
COVID-19: Is there a role for immunonutrition in obese patient?COVID-19:肥胖患者的免疫营养有作用吗?
J Transl Med. 2020 Nov 7;18(1):415. doi: 10.1186/s12967-020-02594-4.
6
Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity.有关维生素 D 与 COVID-19 风险及其严重程度的证据。
Nutrients. 2020 Oct 31;12(11):3361. doi: 10.3390/nu12113361.
7
Azithromycin for severe COVID-19.阿奇霉素用于治疗重症新型冠状病毒肺炎
Lancet. 2020 Oct 3;396(10256):936-937. doi: 10.1016/S0140-6736(20)31863-8. Epub 2020 Sep 5.
8
Azithromycin: The First Broad-spectrum Therapeutic.阿奇霉素:第一种广谱治疗药物。
Eur J Med Chem. 2020 Dec 1;207:112739. doi: 10.1016/j.ejmech.2020.112739. Epub 2020 Aug 19.
9
Bouncing forward: a resilience approach to dealing with COVID-19 and future systemic shocks.向前跃进:一种应对新冠疫情及未来系统性冲击的复原力方法。
Environ Syst Decis. 2020;40(2):174-184. doi: 10.1007/s10669-020-09776-x. Epub 2020 May 25.
10
Secondary Risk Theory: Validation of a Novel Model of Protection Motivation.次级风险理论:一种新型保护动机模型的验证。
Risk Anal. 2021 Jan;41(1):204-220. doi: 10.1111/risa.13573. Epub 2020 Aug 13.

新型冠状病毒肺炎:自我监测清单如何助力早期干预并减缓疾病进展

COVID-19: how a self-monitoring checklist can empower early intervention and slow disease progression.

作者信息

Cummings Christopher L, Miller Craig S

机构信息

Genetic Engineering and Society, Senior Research Fellow, North Carolina State University and Gene Edited Foods Project, Iowa State University, Iowa, USA.

Professor and Chief, Division of Oral Diagnosis, Oral Medicine and Maxillofacial Radiology, College of Dentistry, University of Kentucky, Kentucky, USA.

出版信息

Environ Syst Decis. 2021;41(2):181-183. doi: 10.1007/s10669-021-09806-2. Epub 2021 Mar 8.

DOI:10.1007/s10669-021-09806-2
PMID:33717825
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7938383/
Abstract

The SARS-CoV-2 novel coronavirus pandemic has revealed many scientific, social, and institutional challenges required to improve the health and wellbeing of individuals stricken by this disease. While organizations and governing institutions have risen to the task to concurrently prepare for and respond to this pandemic under conditions of high uncertainty and extreme pressure, another important aspect of this viral infection deserves attention and is not being fully considered, that is early intervention strategies and structured tools for individuals who test positive for the virus and begin developing symptoms. For those whose infection is progressing, we describe the potential benefits of a self-monitoring tool for use in combination with physician directed early medical interventions to slow COVID-19 progression.

摘要

严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)新型冠状病毒大流行揭示了改善受该疾病困扰个体的健康和福祉所需面对的诸多科学、社会及制度方面的挑战。尽管各组织和管理机构已迎难而上,在高度不确定和极端压力的情况下同时为应对这一大流行做准备并做出响应,但这种病毒感染的另一个重要方面值得关注且未得到充分考虑,即针对病毒检测呈阳性并开始出现症状的个体的早期干预策略和结构化工具。对于那些感染病情正在发展的人,我们描述了一种自我监测工具与医生指导的早期医疗干预相结合使用的潜在益处,以减缓2019冠状病毒病(COVID-19)的病情发展。